Lonza acquires Simbiosys Biowares' preclinical cell and molecular biology group

Saturday, 21 November, 2009 | Supplied by: Capsugel Australia Pty Ltd


Lonza has completed the acquisition of the preclinical cell and molecular biology assets of Simbiosys Biowares India, a biology outsourcing company, expanding its cell-biology platform.

Simbiosys’s cell and molecular biology group specialises in primary cell isolation and tissue sourcing and in performing preclinical services to mid-size pharmaceutical companies.

Simbiosys Biowares India offers preclinical services in the areas of: drug discovery services (includes lead validation and lead development using in-vitro and in-vivo ADME-Tox assays); molecular biology contract research services (including DNA amplification and cloning, DNA/RNA isolation, synthetic gene construction and quantitative PCR); biopharmaceutical services (includes process design optimisation of fermentation technology for producing small-molecules, proteins and mAbs for therapeutic, diagnostic and research applications).

Online: lonzabioscience.com.au
Phone: 1300 657508
Related Products

Navinci Diagnostics Naveni CD8/MHC-I Atto647N proximity ligation assay (PLA) kit

The Naveni CD8/MHC-I Atto647N is an in situ proximity ligation assay kit for the detection of the...

Invent Biotechnologies Minute Single Cell Nuclei Kits

The Invent Biotechnologies Minute Single Cell Nuclei Kits use proprietary spin column-based...

MP Biomedicals MagBeads FastDNA MaxPure Kit for Feces and Fecal Preservation Solution

MP Biomedicals MagBeads FastDNA MaxPure Kit for Feces is a magnetic bead-based solution...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd